Seaport Global Securities Initiates Coverage on BioDelivery Sciences International (BDSI)

Investment analysts at Seaport Global Securities started coverage on shares of BioDelivery Sciences International (NASDAQ:BDSI) in a research note issued on Friday, Marketbeat reports. The firm set a “buy” rating and a $5.00 price target on the specialty pharmaceutical company’s stock. Seaport Global Securities’ price objective points to a potential upside of 104.08% from the stock’s previous close.

BDSI has been the subject of a number of other research reports. Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, October 12th. HC Wainwright set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Friday, October 13th. Piper Jaffray Companies set a $4.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Finally, Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $4.38.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down $0.10 during trading hours on Friday, reaching $2.45. 795,311 shares of the company were exchanged, compared to its average volume of 593,051. The company has a market capitalization of $145.30, a P/E ratio of 27.22 and a beta of 0.74. BioDelivery Sciences International has a 52 week low of $1.55 and a 52 week high of $3.60. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The company had revenue of $11.25 million during the quarter, compared to the consensus estimate of $9.40 million. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. BioDelivery Sciences International’s revenue for the quarter was up 215.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. equities analysts anticipate that BioDelivery Sciences International will post 0.16 earnings per share for the current fiscal year.

In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 709,502 shares of BioDelivery Sciences International stock in a transaction on Friday, January 19th. The shares were sold at an average price of $2.73, for a total value of $1,936,940.46. Following the transaction, the director now directly owns 1,759,262 shares of the company’s stock, valued at $4,802,785.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark A. Sirgo sold 162,509 shares of BioDelivery Sciences International stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $2.78, for a total transaction of $451,775.02. Following the completion of the transaction, the director now directly owns 1,759,262 shares in the company, valued at $4,890,748.36. The disclosure for this sale can be found here. Insiders sold 980,011 shares of company stock worth $2,666,275 over the last ninety days. Corporate insiders own 9.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its holdings in shares of BioDelivery Sciences International by 138.2% during the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 20,599 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of BioDelivery Sciences International during the third quarter valued at $116,000. Advisor Group Inc. grew its holdings in shares of BioDelivery Sciences International by 42.1% during the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 13,341 shares during the last quarter. Northern Trust Corp grew its holdings in shares of BioDelivery Sciences International by 0.9% during the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after buying an additional 1,203 shares during the last quarter. Finally, Krilogy Financial LLC grew its holdings in shares of BioDelivery Sciences International by 28.8% during the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock valued at $395,000 after buying an additional 30,000 shares during the last quarter. 44.25% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Seaport Global Securities Initiates Coverage on BioDelivery Sciences International (BDSI)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/26/seaport-global-securities-initiates-coverage-on-biodelivery-sciences-international-bdsi.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply